The Spanish biotech firm, founded in 1986, calls itself a world leader in the discovery of antitumor drugs of marine origin.

PharmaMar develops and commercializes Yondelis (trabectedin) in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers including Zepsyre (lurbinectedin), plitidepsin, PM184 and PM14.